(Q33834135)

29 July 2017

title

A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa (English)

1 reference

29 July 2017

Robert A Lee

1

1 reference

29 July 2017

Erica Dommasch

2

1 reference

29 July 2017

James Treat

3

1 reference

29 July 2017

Joslyn Sciacca-Kirby

4

1 reference

29 July 2017

Samuel Chachkin

5

1 reference

29 July 2017

Jennifer Williams

6

1 reference

29 July 2017

Daniel B Shin

7

1 reference

29 July 2017

James J Leyden

8

1 reference

29 July 2017

Carmela Vittorio

9

1 reference

29 July 2017

Joel M Gelfand

10

1 reference

29 July 2017

language of work or name

English

0 references

publication date

31 January 2009

1 reference

Journal of the American Academy of Dermatology

29 July 2017

published in

1 reference

29 July 2017

volume

60

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

565-573

1 reference

Hidradenitis suppurativa: an update

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Quality of life impairment in hidradenitis suppurativa: a study of 61 cases

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Etanercept: effective in the management of hidradenitis suppurativa

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Medical treatment of hidradenitis suppurativa

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Infliximab for hidradenitis suppurativa

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Optimal two-stage designs for phase II clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Hidradenitis suppurativa--characteristics and consequences.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

The prevalence of hidradenitis suppurativa and its potential precursor lesions.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2865694

Acne inversa treated with infliximab: different outcomes in 2 patients

29 October 2018

1 reference

12 December 2020

Efficacy of Infliximab treatment in patients with severe Fistulizing Hidradenitis Suppurativa

1 reference

12 December 2020

Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab

1 reference

12 December 2020

Hidradenitis suppurativa of glands of Moll

1 reference

12 December 2020

Variable response of hidradenitis suppurativa to infliximab in four patients

1 reference

12 December 2020

Infliximab for the treatment of hidradenitis suppurativa

1 reference

12 December 2020

Severe hidradenitis suppurativa treated with infliximab infusion

1 reference

12 December 2020

Long-term efficacy of etanercept in hidradenitis suppurativa

1 reference

12 December 2020

The cutting edge. Severe hidradenitis suppurativa treated with adalimumab

1 reference

12 December 2020

Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases

1 reference

12 December 2020

Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients

1 reference

12 December 2020

Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease

1 reference

12 December 2020

10.1016/J.JAAD.2008.11.898

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference